5-α-Reductase inhibition and prostate cancer prevention

Otis W. Brawley, Leslie G. Ford, Ian Thompson, Jeffrey A. Perlman, Barnett S. Kramer

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume3
Issue number2
StatePublished - 1994

Fingerprint

Dihydrotestosterone
Prostate
Prostatic Neoplasms
Oxidoreductases
Finasteride
Enzyme Inhibitors
Growth
Androgens
Testosterone
Randomized Controlled Trials
Placebos
Incidence
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Brawley, O. W., Ford, L. G., Thompson, I., Perlman, J. A., & Kramer, B. S. (1994). 5-α-Reductase inhibition and prostate cancer prevention. Cancer Epidemiology Biomarkers and Prevention, 3(2), 177-182.

5-α-Reductase inhibition and prostate cancer prevention. / Brawley, Otis W.; Ford, Leslie G.; Thompson, Ian; Perlman, Jeffrey A.; Kramer, Barnett S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 3, No. 2, 1994, p. 177-182.

Research output: Contribution to journalArticle

Brawley, OW, Ford, LG, Thompson, I, Perlman, JA & Kramer, BS 1994, '5-α-Reductase inhibition and prostate cancer prevention', Cancer Epidemiology Biomarkers and Prevention, vol. 3, no. 2, pp. 177-182.
Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-α-Reductase inhibition and prostate cancer prevention. Cancer Epidemiology Biomarkers and Prevention. 1994;3(2):177-182.
Brawley, Otis W. ; Ford, Leslie G. ; Thompson, Ian ; Perlman, Jeffrey A. ; Kramer, Barnett S. / 5-α-Reductase inhibition and prostate cancer prevention. In: Cancer Epidemiology Biomarkers and Prevention. 1994 ; Vol. 3, No. 2. pp. 177-182.
@article{cab0030a64a2414d96a62b854331925d,
title = "5-α-Reductase inhibition and prostate cancer prevention",
abstract = "Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.",
author = "Brawley, {Otis W.} and Ford, {Leslie G.} and Ian Thompson and Perlman, {Jeffrey A.} and Kramer, {Barnett S.}",
year = "1994",
language = "English (US)",
volume = "3",
pages = "177--182",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - 5-α-Reductase inhibition and prostate cancer prevention

AU - Brawley, Otis W.

AU - Ford, Leslie G.

AU - Thompson, Ian

AU - Perlman, Jeffrey A.

AU - Kramer, Barnett S.

PY - 1994

Y1 - 1994

N2 - Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.

AB - Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.

UR - http://www.scopus.com/inward/record.url?scp=0028243902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028243902&partnerID=8YFLogxK

M3 - Article

C2 - 8049641

AN - SCOPUS:0028243902

VL - 3

SP - 177

EP - 182

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -